Municipal Employees Retirement System of Michigan Invests $201,000 in Amphastar Pharmaceuticals Inc (AMPH)

Municipal Employees Retirement System of Michigan purchased a new position in Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,120 shares of the company’s stock, valued at approximately $201,000.

Other large investors have also bought and sold shares of the company. Texas Permanent School Fund raised its stake in Amphastar Pharmaceuticals by 3.6% during the fourth quarter. Texas Permanent School Fund now owns 22,624 shares of the company’s stock worth $450,000 after purchasing an additional 796 shares during the period. LS Investment Advisors LLC raised its stake in Amphastar Pharmaceuticals by 217.9% during the fourth quarter. LS Investment Advisors LLC now owns 3,522 shares of the company’s stock worth $70,000 after purchasing an additional 2,414 shares during the period. Legal & General Group Plc raised its stake in Amphastar Pharmaceuticals by 3.6% during the third quarter. Legal & General Group Plc now owns 74,224 shares of the company’s stock worth $1,425,000 after purchasing an additional 2,568 shares during the period. Arizona State Retirement System raised its stake in Amphastar Pharmaceuticals by 5.8% during the fourth quarter. Arizona State Retirement System now owns 53,243 shares of the company’s stock worth $1,060,000 after purchasing an additional 2,918 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in Amphastar Pharmaceuticals during the fourth quarter worth about $63,000. 47.57% of the stock is currently owned by hedge funds and other institutional investors.

In other Amphastar Pharmaceuticals news, insider Jason B. Shandell sold 32,336 shares of Amphastar Pharmaceuticals stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $20.35, for a total transaction of $658,037.60. Following the completion of the sale, the insider now directly owns 160,490 shares in the company, valued at $3,265,971.50. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Jason B. Shandell sold 15,497 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, January 23rd. The shares were sold at an average price of $22.39, for a total transaction of $346,977.83. Following the sale, the insider now owns 168,518 shares of the company’s stock, valued at $3,773,118.02. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 113,122 shares of company stock valued at $2,561,811. Company insiders own 31.50% of the company’s stock.

A number of equities analysts have commented on the stock. BidaskClub downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, April 10th. TheStreet downgraded shares of Amphastar Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, March 18th. Needham & Company LLC downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating and set a $22.20 target price on the stock. in a research note on Wednesday, March 13th. Piper Jaffray Companies downgraded shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $24.00 to $23.00 in a research note on Wednesday, March 13th. Finally, Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, March 5th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $23.73.

Shares of AMPH opened at $20.58 on Wednesday. Amphastar Pharmaceuticals Inc has a 1-year low of $14.40 and a 1-year high of $25.43. The stock has a market cap of $973.21 million, a price-to-earnings ratio of 90.43, a P/E/G ratio of 2.38 and a beta of 1.37. The company has a quick ratio of 1.41, a current ratio of 2.06 and a debt-to-equity ratio of 0.09.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its quarterly earnings results on Tuesday, March 12th. The company reported $0.13 earnings per share for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Amphastar Pharmaceuticals had a negative net margin of 1.96% and a positive return on equity of 3.17%. The business had revenue of $89.69 million during the quarter, compared to analysts’ expectations of $75.46 million. As a group, equities research analysts predict that Amphastar Pharmaceuticals Inc will post 0.35 earnings per share for the current fiscal year.

WARNING: “Municipal Employees Retirement System of Michigan Invests $201,000 in Amphastar Pharmaceuticals Inc (AMPH)” was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thelincolnianonline.com/2019/04/17/municipal-employees-retirement-system-of-michigan-invests-201000-in-amphastar-pharmaceuticals-inc-amph.html.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients products.

Featured Story: What is Net Asset Value (NAV)?

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.